Results 171 to 180 of about 3,811,568 (245)

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. [PDF]

Cancer
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI.   +11 more
europepmc   +1 more source

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. [PDF]

Future Oncol
Bryce AH, Nash P, Roessler A, Mandair D.
europepmc   +1 more source

A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Cancer Res Commun
Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI.   +25 more
europepmc   +1 more source

Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting. [PDF]

BBA Adv
Wang CL, Lv JT, Liu SJ, Zhang YY, Wang SL, Song SQ.   +5 more
europepmc   +1 more source

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort. [PDF]

J Nucl Med
Bauckneht M, Belgioia L, Albano D, Triggiani L, Linguanti F, Urso L, Mazzola R, Rizzo A, D'Angelo E, Dondi F, Mataj E, Pedersoli G, Abenavoli EM, Vaggelli L, Detti B, Ortolan N, Malorgio A, Guarneri A, Garrou F, Passoni J, Fiorini M, Grimaldi S, Ghedini P, Iorio GC, Iudicello A, Rovera G, Fornarini G, Zanardi E, Bongiovanni D, Marcenaro M, Agosti A, Timon G, Salgarello M, Racca M, Bartolomei M, Panareo S, Ricardi U, Bertagna F, Alongi F, Barra S, Morbelli S, Lanfranchi F, Sambuceti G.   +42 more
europepmc   +1 more source

Magnocurarine inhibits migration and invasion by suppressing mesenchymal marker expression and MAPK signaling in castration-resistant prostate cancer cells. [PDF]

Front Pharmacol
Semmarath W, Arjsri P, Srisawad K, Thippraphan P, Intanil I, Umsumarng S, Dejkriengkraikul P.   +6 more
europepmc   +1 more source

Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer. [PDF]

J Clin Invest
Sahu R, Enos M, Sharma S, Schade AE, Gardner A, Yoshinaga A, Indeglia A, Minogue E, Hu S, Kurmi K, Joshi S, Schmidt DR, Yaffe S, Nguyen VT, Xie F, Balk SP, Vander Heiden MG, Helin K, Haigis MC, Cichowski K.   +19 more
europepmc   +1 more source

Engineered human adipose-derived stem cells delivering carboxylesterase and TRAIL for castration-resistant prostate cancer: Translational synthesis. [PDF]

Investig Clin Urol
Kim JH, Lee SH, Song YS.
europepmc   +1 more source

Erratum: [Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Oncol Lett
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y, Feng F.   +6 more
europepmc   +1 more source